Enhanced Cytotoxicity of Human Hepatocellular Carcinoma Cells Following Pretreatment with Sorafenib Combined with Trichostatin A

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jan 19

PMID 30655811

Citations 7

Authors

John Chun-Hao Chen

Hui-Yen Chuang

Yi-Jen Liao

Fei-Ting Hsu

Yen-Chung Chen

Wei-Hsun Wang

Jeng-Jong Hwang

Affiliations

Soon will be listed here.

Abstract

Trichostatin A (TSA), a hydroxamate histone deacetylase inhibitor, is a compound that has been identified to induce anticancer activity. The aim of the present study was to investigate whether sorafenib, in combination with TSA, was able to augment the anticancer effects of TSA, identifying an optimum treatment time plan and the potential underlying molecular mechanisms involved in human hepatocellular carcinoma (HCC) . Huh7/nuclear factor-κB (NF-κB)- cells were treated with TSA or sorafenib alone, or sorafenib, prior to, in combination with or following TSA treatment. Huh7/NF-κB- cell viability following TSA treatment was determined using an MTT assay, and NF-κB activity was analyzed. In addition, the expression levels of NF-κB-regulated downstream effector proteins were assayed by western blotting. Inhibitors of mitogen-activated protein kinases (MAPKs), protein kinase B (AKT) and mutant inhibitor of NF-κBα (IκBαM) vectors were used to confirm the function of the NF-κB signal transduction pathways in response to the effects of sorafenib combined with TSA against HCC. The results of the present study indicated that pre-treatment with sorafenib followed by TSA inhibited the cell viability compared with other treatment modalities, and prevented TSA-induced extracellular-signal-regulated kinase (ERK)/NF-κB activity and expression of downstream effector proteins. It was further demonstrated that IκBαM vector sensitized Huh7/NF-κB- cells to TSA, thus it was possible to reverse TSA-induced NF-κB activity using PD98059, a MAPK/ERK kinase inhibitor. In conclusion, sorafenib pre-treatment may increase the efficacy of subsequent TSA treatment in HCC. Furthermore, sorafenib pre-treatment is hypothesized to sensitize HCC to TSA via the inhibition of the MEK/ERK/NF-κB signal transduction pathway.

Citing Articles

Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation.

Chiang C, Yang J, Liu W, Chang F, Yang C, Hsu K Cancer Cell Int. 2025; 25(1):47.

PMID: 39955573 PMC: 11829490. DOI: 10.1186/s12935-024-03597-7.

Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis.

Li Y, Yan J, Sun H, Liang Y, Zhao Q, Yu S Int J Biol Sci. 2024; 20(7):2622-2639.

PMID: 38725840 PMC: 11077382. DOI: 10.7150/ijbs.86479.

Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.

El-Hazek R, Zaher N, El-Gazzar M, Fadel N, El-Sabbagh W Sci Rep. 2023; 13(1):13907.

PMID: 37626064 PMC: 10457369. DOI: 10.1038/s41598-023-40832-z.

Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib.

Jiang Z, Dai C J Hepatocell Carcinoma. 2023; 10:257-266.

PMID: 36815094 PMC: 9939808. DOI: 10.2147/JHC.S396231.

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.

Tao S, Liang S, Zeng T, Yin D Front Immunol. 2023; 13:1043667.

PMID: 36685594 PMC: 9845774. DOI: 10.3389/fimmu.2022.1043667.

References

Tai D, Tsai S, Chang Y, Huang S, Chen T, Chang K . Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer. 2001; 89(11):2274-81. View

Ly J, Grubb D, Lawen A . The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003; 8(2):115-28. DOI: 10.1023/a:1022945107762. View

Rosato R, Almenara J, Grant S . The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003; 63(13):3637-45. View

Rundall B, Denlinger C, Jones D . Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery. 2004; 136(2):416-25. DOI: 10.1016/j.surg.2004.05.018. View

Coradini D, Speranza A . Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin. 2005; 26(9):1025-33. DOI: 10.1111/j.1745-7254.2005.00195.x. View

Yao J, Duan L, Fan M, Wu X . NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. Pharmacol Res. 2006; 54(6):406-13. DOI: 10.1016/j.phrs.2006.08.003. View

Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H . Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol. 2007; 13(33):4458-66. PMC: 4611578. DOI: 10.3748/wjg.v13.i33.4458. View

Pan L, Lu J, Huang B . HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol. 2007; 4(5):337-43. View

Domingo-Domenech J, Pippa R, Tapia M, Gascon P, Bachs O, Bosch M . Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat. 2007; 112(1):53-62. DOI: 10.1007/s10549-007-9837-8. View

10.

Zhang G, Park M, Mitchell C, Hamed H, Rahmani M, Martin A . Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res. 2008; 14(17):5385-99. PMC: 2561272. DOI: 10.1158/1078-0432.CCR-08-0469. View

11.

Komarova N, Katouli A, Wodarz D . Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One. 2009; 4(2):e4423. PMC: 2635955. DOI: 10.1371/journal.pone.0004423. View

12.

Duvic M, Vu J . Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics. 2009; 1(4):377-92. PMC: 2721288. View

13.

Pan C, Kavanagh B, Dawson L, Li X, Das S, Miften M . Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S94-100. PMC: 4388033. DOI: 10.1016/j.ijrobp.2009.06.092. View

14.

Li W, Tan D, Zenali M, Brown R . Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol. 2010; 3(3):238-43. PMC: 2836501. View

15.

Dai Y, Guzman M, Chen S, Wang L, Yeung S, Pei X . The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol. 2010; 151(1):70-83. PMC: 2950247. DOI: 10.1111/j.1365-2141.2010.08319.x. View

16.

Mund C, Lyko F . Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays. 2010; 32(11):949-57. DOI: 10.1002/bies.201000061. View

17.

Kuo Y, Lin W, Chiang I, Chang Y, Chen C, Su S . Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. Biomed Pharmacother. 2012; 66(1):12-20. DOI: 10.1016/j.biopha.2011.09.011. View

18.

Yan G, Graham K, Lanza-Jacoby S . Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog. 2012; 52(5):404-11. DOI: 10.1002/mc.21875. View

19.

Liu Y, Chiang I, Hsu F, Hwang J . Using NF-κB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn. 2012; 12(2):139-46. DOI: 10.1586/erm.12.2. View

20.

Chiang I, Liu Y, Wang W, Hsu F, Chen H, Lin W . Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. In Vivo. 2012; 26(4):671-81. View